Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Harry M. Meade
Advertisement
Harry M. Meade, PhD, is senior vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Harry M. Meade
Advertisement
Latest Updated Articles
Production of Recombinant Therapeutic Proteins in the Milk of Transgenic AnimalsPublished: August 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Futureproofing Viral Safety: Global Perspectives from an Educator, Supplier, and Biosafety Expert
5
